Drug intelligence / Profile preview

DW1125A

Development stage: Unknown
Lead developer: Daewon Pharm
Modality: Small Molecules
Administration: Oral

Overview

DW1125A is an investigational drug developed for the treatment of primary hypercholesterolemia or mixed dyslipidemia. It is being evaluated in randomized, double-blind, parallel, multi-center Phase 3 clinical trials to assess its efficacy and safety compared to other lipid-lowering agents such as ezetimibe/atorvastatin combinations and atorvastatin alone[4][10]. The specific mechanism of action for DW1125A has not been publicly detailed in available sources; however, it is likely a small molecule targeting lipid metabolism pathways relevant to cholesterol management. The developer and sponsor of the clinical trials is Daewon Pharmaceutical Co., Ltd.[3][10].

Other names: atorvastatin 5mgatorvastatin5mgatorvastatin-5mgatorvastatin (Daewon Pharmaceutical)

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on DW1125A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW1125A.

Explore the full profile